By integrating phase separation biology with metabolic and immune checkpoints, the work supports a condensate-linked regulatory axis and motivates hypothesis-driven strategies: stabilizing or mimicking TIA1-dependent glycolytic restraint should be explored cautiously to potentially enhance intravesical BCG and other immunotherapies in bladder cancer pending further validation. Here, TIA1 is linked to urinary bladder cancer.